New opioid approved for use in controlled settings

white pill
Credit: Pixabay/CC0 Public Domain

The opioid Olinvyk (oliceridine) was granted approval for the management of moderate-to-severe acute pain in controlled settings, the U.S. Food and Drug Administration announced Friday.

Olinvyk is indicated for short-term intravenous use in adults with pain that is severe enough to require an intravenous and who are inadequately treated with other alternatives. The drug is approved only for use in hospitals or other controlled settings and is not for at-home use. The maximum recommended daily dose is 27 mg.

Approval was based on phase 3 data from clinical and open-label trials that included a total of 1,535 with moderate-to-severe acute pain. Compared with patients randomly assigned to placebo, those who received Olinvyk after bunion or abdominal surgery reported decreased pain.

As with other opioids, common side effects of Olinvyk are nausea, vomiting, dizziness, headache, and constipation. Olinvyk is contraindicated for patients with significant , acute or severe bronchial asthma in an unmonitored setting, gastrointestinal obstruction, or known hypersensitivity to Olinvyk. The drug label includes a boxed warning on the risks for addiction, abuse, and misuse; life-threatening respiratory depression; and neonatal opioid withdrawal syndrome, as well as the risks of taking the drug simultaneously with benzodiazepines or other central nervous system antidepressants. Approval was granted to Trevena.


Explore further

Oliceridine studied for IV pain relief after abdominoplasty

More information: More Information from the FDA: www.fda.gov/news-events/press- … ed-clinical-settings

Health News Copyright © 2020 HealthDay. All rights reserved.

Citation: New opioid approved for use in controlled settings (2020, August 11) retrieved 23 October 2020 from https://medicalxpress.com/news/2020-08-opioid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments